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Abstract
Background: Clinical evidence has been controversial regarding the influence of low platelet reactivity 
(LPR), ischemic and bleeding outcomes among patients receiving coronary stent implantation. Hence, 
the present study performed a meta-analysis to systematically evaluate the significance of LPR on ad-
verse cardiovascular events.
Methods: MEDLINE, EMBASE and CENTRAL databases were searched up to November 2020 for 
relevant studies including patients with acute coronary syndrome undergoing percutaneous coronary 
intervention. LPR was the exposed arm while the non-LPR group represented the control. The primary 
outcome of interest was bleeding risk including major and minor bleeding events. Secondary outcomes 
included all-cause mortality, repeated revascularization, nonfatal myocardial infarction, and stent 
thrombosis. Study-level outcomes were evaluated in random-effect models.
Results: A total of 20 studies with 19,064 patients were included. Pooled analysis showed that LPR 
was associated with an increased bleeding risk (relative risk [RR] 2.80, 95% confidence interval [CI] 
1.95–4.02, p < 0.01). Patients with LPR had a lower risk of non-fatal myocardial infarction (RR 0.59, 
95% CI 0.38–0.91, p < 0.05) and of serious vascular events (RR 0.50, 95% CI 0.30–0.84, p < 0.01). 
Conclusions: Low platelet reactivity is associated with an increased bleeding risk of patients who 
underwent coronary stent implantation. The results suggest possible benefits of this marker in risk 
stratification, with potential improvement in risk prediction. There are potential advantages using 
combinations with other factors in prediction models, however, they require further study. PROSPERO 
registration number: CRD42019136393). (Cardiol J)
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Dual antiplatelet therapy consisting of ace-
tylsalicylic acid and adenosine diphosphate (ADP) 
receptor antagonist is essential for patients un-
dergoing percutaneous coronary intervention 
(PCI) [1]. Clopidogrel used to be the gold standard 
therapy before the introduction of new P2Y12 
inhibitors, such as prasugrel and ticagrelor, which 
have demonstrated their clinical advantages in 
large randomized controlled trials (RCTs) involv-
ing acute coronary syndrome (ACS) patients [2, 
3]. Both prasugrel and ticagrelor provide more 
effective inhibition of platelet function than ace-
tylsalicylic acid, however, their use was followed 
by an increased bleeding risk [2, 3]. 
Platelet function testing assesses individual 
response to antiplatelet drugs and platelet reactiv-
ity (PR) strongly relates to clinical outcomes after 
ACS [4–6]. Numerous studies have shown a rela-
tionship between high platelet reactivity (HPR) and 
thrombotic events [7–9]. Recent studies have also 
found that platelet function testing and/or genetic 
testing may provide important information guiding 
antiplatelet therapy [10, 11]. 
With the use of more effective agents, the 
prevalence of HPR has decreased and an increasing 
proportion of patients have very low on-treatment 
ADP reactivity. However, the clinical significance of 
low platelet ractivity (LPR) is less well established 
and it is not routinely measured. The effect of LPR 
was investigated in some studies raising a signal 
of increased bleeding risk which remains debated, 
partly due to contradictory results [12–14]. The ob-
jective herein, was to perform a systematic review 
and meta-analysis aimed at assessing the impact 
of LPR on efficacy and safety outcomes after PCI.
Methods
Search strategy
A systematic review and meta-analysis were 
performed with reference to the PRISMA guideline 
[15]. The National Library of Medical Publications 
(MEDLINE); including its subset, PubMed, the Ex-
cerpta Medica Database (EMBASE) and Cochrane 
Library databases were searched for relevant 
articles with no restriction of time in November 
2020 by using a search strategy that combined 
the following: Medical Subject Headings and free-
text search terms: “acute coronary syndrome” 
OR “ACS” AND “PCI” OR “percutaneous coro-
nary intervention” AND “platelet reactivity” OR 
“thrombocyte reactivity”. No language restriction 
was used. The PICO format was adapted to set the 
inclusion criteria. The PICO items selected were 
the following: (P) patients with ACS and/or under-
going PCI and receiving dual antiplatelet therapy 
consisting of acetylsalicylic acid and clopidogrel, 
prasugrel or ticagrelor, (I) LPR (C) non-LPR or 
HPR based on the measurement of on-treatment 
PR defined by an ADP-specific platelet function as-
say and (O) major adverse cardiac events (MACE) 
and bleeding. The non-LPR group consisted of 
HPR or HPR plus normal platelet reactivity (NPR) 
where data was given for NPR. The clinical out-
comes of interest evaluated at the longest available 
follow-up of ADP-receptor inhibitor treatment were 
(a) major bleeding events (defined using the trials 
internal definitions using Bleeding Academic Re-
search Consortium [BARC] 3–5 or Thrombolysis 
in Myocardial Infarction [TIMI] major criteria), 
and (b) minor bleeding events (BARC 1–2 or TIMI 
minor) [16], (c) definite/probable stent thrombosis, 
(d) non-fatal myocardial infarction (MI) (type 1, 4a, 
4b), (e) a composite endpoint of the reported serious 
vascular events that included cardiovascular death, 
non-fatal MI or non-fatal stroke, (f) repeated target 
vessel revascularization, and (g) all-cause mortality.
Studies that assessed responsiveness to clopi-
dogrel, which was the difference between baseline 
and posttreatment PR (inhibition of platelet aggre-
gation), were excluded from the analysis. The 
reference lists in the articles were also checked to 
capture all relevant articles published within the 
topic of interest.  
Data extraction 
Observational studies and cohorts — regard-
less of their prospective/retrospective design 
— were identified. Two investigators (A.B. and 
A.K.) independently screened the retrieved titles, 
abstracts and studies for eligibility and relevant full 
texts were systematically retrieved for further as-
sessment. Disagreements between reviewers were 
solved by consensus. The retrieved studies were 
examined to exclude duplicate or overlapping data. 
Unpublished data and meeting abstracts were not 
considered for the present analysis because results 
could not be considered as certain and definitive. 
Risk of bias
The methodological qualities of the studies 
were assessed using the Prediction model Risk 
Of Bias Assessment Toll (PROBAST) for asse-
ssing the quality of cohorts and the Newcastle-
Ottawa Scale with reference to observational 
studies [17, 18]. 
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Publication bias was estimated using funnel 
plots. Visual evaluation and Egger’s regression 
intercept were used to the check for asymmetry.
Statistical analysis
Statistical computations were performed us-
ing R (v 4.0.03) package ‘dmetar’ designed for 
the evaluation of meta-analyses and OpenMe-
ta [Analyst] open source statistical softwares. 
A random-effect model was applied at all the 
analyses with DerSimonian-Laird estimation to 
derive risk ratios (RR) on dichotomous outcomes 
and weighted mean difference on continuous data 
with a 95% confidence interval [CI]. Heterogeneity 
was tested with the c2 heterogeneity statistic for 
which a p-value < 0.1 was considered potentially 
heterogenous. Consistency was assessed using 
I2 statistics [19]. Sensitivity analyses were carried 
out omitting one study at a time and calculating the 
effect size with the 95% CI to investigate the influ-
ence that a single study has on the final estimation 
regarding LPR with increased bleeding risk.
Ethical approval
Ethical or board review approval was not re-
quired for this meta-analysis.
Results 
Search results and effect of LPR on the clini-
cal outcomes 
Twenty studies, involving 19,064 patients met 
the inclusion criteria. The process of the literature 
search and bias assessment is summarized in Figure 1 
and for online Supplementary Figure S4.
Table 1 describes the main characteristics 
of the included studies [7, 13, 20–36]. Based on 
pooled results of the random-effects model meta-
analysis, LPR was associated with a significantly 
increased risk for major and minor bleeding events 
compared to non-LPR (RR 2.80, 95% CI 1.95–4.02, 
p < 0.01) (Fig. 2).  
Patients with LPR had significantly lower risk 
of non-fatal MI and of serious vascular events (RR 
0.59, 95% CI 0.38–0.91, p < 0.05 and RR 0.50, 
95% CI 0.30–0.84, p < 0.01, respectively; Fig. 3). 
The risk for stent trombosis was 45% lower in the 
case of LPR, however, this difference did not reach 
the level of statistical significance (RR 0.55, 95% 
CI 0.27–1.11, p = 0.10; Fig. 3). Even though the 
mortality of LPR patients was numerically higher 
the difference between the two groups remained 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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Alexandra Bálint et al., Bleeding risk associated with LPR
Figure 3. Summary of the outcomes of the secondary endpoints. The diamond represents the cumulative risk 
ratio and confidence interval (CI) of all patient groups. *Mean difference (95% CI); LPR — low platelet reactivity; 
MI — myocardial infarction.
Figure 2. Principal pooled analysis. Forest plots of major and minor bleeding risk in studies following percutaneous 
coronary intervention with low platelet reactivity (LPR) versus without LPR. The grey rectangles are proportional with 
the study weight. The diamond represents the cumulative odds ratio (OR) and confidence interval (CI).
Fig. 3). No significant difference was found regard-
ing repeated revascularization (RR 0.96, 95% CI 
0.57–1.60, p = 0.84; Fig. 3). Body mass index was 
significantly lower in the LPR group (standardized 
mean difference –0.18, 95% CI –0.32 to –0.05, 
p < 0.01; Suppl. Fig. S1).
Heterogeneity and subgroup analyses 
The rate of LPR demonstrated a mean preva-
lence of 27% (95% CI for mean 20–35%, range 4.5–
–82%). Overall heterogeneity concerning major and 
minor bleeding events was considerable (I2 = 80%, 
p < 0.01). To find possible determinants of the 
6 www.cardiologyjournal.org
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observed heterogeneity, the prevalence of LPR 
and bleeding events was analyzed according to the 
following grouping factors: type of platelet function 
device, definition of bleeding events and amount 
of clopidogrel loading dose (LD).
The analysis confirmed that all the selected 
ADP-specific assays were able to predict the oc-
currence of bleeding events and the higher risk 
of patients with LPR was consistent regardless 
of the clinical presentation. Noticeably, consider-
able heterogeneity was observed in the results 
between studies using VASP-P and Verify Now 
assays; however, the Multiplate assay showed more 
homogenous findings (Suppl. Fig. S2). Subgroup 
analysis was also performed to assess the potential 
influence of different clopidogrel LD regimes. De-
spite the different types of clopidogrel loading dose, 
heterogeneity remained high (Suppl. Fig. S2).
When bleeding events were divided into ma-
jor and minor events separately the heterogene-
ity was reduced considerably for major bleeding 
(I2 = 34%) while heterogeneity remained high for 
minor bleeding (I2 = 82%; Suppl. Fig. S3).
Publication bias
Based on visual estimation of the funnel plot 
for bleeding events, no major asymmetry sugges-
tive for publication bias was found. Furthermore, 
Egger’s regression test confirms no small-study 
effect (Suppl. Fig. S4). Analysis of bias showed 
high quality of the source information with low 
probability of possible bias (Suppl. Fig. S4).
Discussion
The key finding of this meta-analysis is that 
patients with LPR after PCI are at a higher risk 
of bleeding. LPR detected by an ADP-specific 
laboratory assay is also associated with a lower 
risk of non-fatal MI. The composite endpoint 
of serious vascular events demonstrated lower 
risk with LPR. All-cause mortality did not differ 
significantly between LPR and non-LPR patient 
groups. Importantly, despite the differences in the 
methodology, patient selection and cut-off defini-
tion among studies, the increased risk of bleeding 
was homogenously reflected. 
To date, this is the first meta-analysis of stud-
ies testing the role of LPR on bleeding and ischemic 
events in patients who underwent PCI.
In the first study reporting on the impact 
of enhanced response to clopidogrel treatment 
including 2,533 patients with coronary artery 
disease undergoing planned PCI, LPR was found 
to be associated with a two-fold higher risk for in-
hospital major bleeding events [7]. Further reports 
suggested that LPR is a marker for a higher risk 
of bleeding events also among prasugrel-treated 
patients [25, 26]. 
Some recent studies, however, do not neces-
sarily support that optimal PR does denote the 
same range in every patient population. In the 
TRILOGY ACS trial involving ACS patients with-
out PCI, the relationship between LPR and risks 
of major bleeding was missing. Among medically 
managed non-ST-segment elevation ACS patients 
receiving prolonged dual antiplatelet therapy, 
platelet reactivity unit values were not signifi-
cantly associated with the long-term risk of major 
bleeding events, suggesting that LPR does not 
independently predict serious bleeding risk [37].
Aimed at assessing the potential influence 
of different clopidogrel LD regimes, a subgroup 
analysis was performed. The results showed no 
association between different LDs of clopidogrel 
and rate of bleeding events. These findings are in 
line with a recent meta-analysis that compared the 
use of different LDs of clopidogrel and found that 
these are not associated with an increased risk for 
major bleeding within 30 days. However, it also 
suggested that the administration of 600 mg LD of 
clopidogrel is associated with a lower risk of MACE 
[38]. This observation is further supported by 
a retrospective study of patients with stable coro-
nary artery disease which shows no difference 
between different LD groups in terms of major 
bleeding and hemoglobin drop post PCI [39]. 
When interpreting data from platelet func-
tion studies, the complex mechanisms of bleeding 
should be considered. Besides the potential impact 
of platelet inhibition, several clinical factors also 
influence the risk of these events. Residual PR, 
as an independent risk factor also has several as-
sociations with patient characteristics and these 
may also influence the expressed risk. HPR is 
more frequently encountered in obese and diabet-
ics, while LPR may more likely arise in patients 
with advanced age and lower body weight [40, 41]. 
A significant association of LPR was revealed with 
lower body mass index in the current analysis. 
These characteristics may also impact the prog-
nosis and when analyzed in multivariate models, 
the magnitude of risk, as in cases of ischemic risk 
with HPR, this risk is considerably reduced [42]. 
Importantly, periprocedural bleeding risk is 
substantially influenced by the access site selec-
tion, being significantly higher with transfemoral 
interventions. Bleeding avoidance strategies like 
www.cardiologyjournal.org 7
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routine use of the transradial approach may in-
terfere with this risk by reducing bleeding and 
improving outcomes among high-risk ACS patient 
[43]. In the present analysis, the rate of transradial 
approach reached 59% (reported in 8 studies in-
cluding 8,667 [45%] patients). However, since this 
data was not presented in a considerable propor-
tion of studies this impedes the further analysis of 
potential impact of access site selection. 
The findings herein, are partly in line with 
the results of a previous meta-analysis published 
in 2015 including 17 trials with a total of 20,839 
patients validating standardized cut-off points for 
platelet function testing. In that study thienopyr-
idine-treated patients with HPR were associated 
with 2.73-fold higher risk for stent trombosis 
(p < 0.00001) and a 1.5-fold higher risk for mortal-
ity (p < 0.05) compared with those with optimal 
PR following PCI, meanwhile patients with LPR 
were associated with a 2-fold increased risk for 
major bleeding complications without any further 
reduction in the risk of stent trombosis [38]. In the 
present study, there was no significant difference 
between LPR and non-LPR groups in case of mor-
tality, stent trombosis or repeated revasculariza-
tion. However, the risk of serious vascular events 
resulted in a significant difference favoring the LPR 
group. Regarding risk of non-fatal MI, the event 
rate was significantly lower in the LPR group. 
However, there are some limitations that 
may impact the interpretation of the current re-
sults. Observational studies were included that 
are usually unbalanced regarding baseline clinical 
characteristics of the patients. These studies could 
reflect the real-world practice better, meanwhile 
due to a lack of monitoring drug compliance, 
underreporting negative results and incomplete 
follow-up, their interpretation may be more difficult 
and might carry ascertainment biases. To balance 
possible confounding factors, data were pooled 
with logarithmic transformation according to the 
random-effect model via generic inverse weight-
ing with the intent of methodical compensation of 
these factors. 
It should be mentioned that the patients 
were not treated uniformly regarding the LDs of 
clopidogrel and that platelet function assessments 
were performed at different time points after PCI 
with different devices and cut-offs for LPR that 
may have contributed to heterogeneity. There are 
multiple tests in the field with a real-gold standard 
evidently missing. Considering the plethora of 
available platelet function tests, the aim to restrict 
the analyses to those that implement a method 
based on ADP dependent in vitro platelet activation 
was used in order to best assess the efficacy of ADP 
receptor dependent activation pathway. From this 
perspective, acceptable methodologies were not 
restricted based on the final readout of the method. 
The use of different P2Y12 inhibitors may also 
have influenced residual platelet reactivity. Due 
to a lack of patient-level data, subgroup analyses 
were not done to identify drug related efficacy. It 
is also important to note that different definitions 
of bleeding may have contributed to heterogeneity. 
The aim to collect data according to the two most 
widely used and standardized definitions, the TIMI 
bleeding and BARC criteria were used. 
Conclusions
In conclusion, this meta-analysis supports that 
LPR is associated with important clinical outcomes 
of patients who underwent coronary stent implan-
tation. The possible benefit of this marker in risk 
stratification or improvement of risk prediction, if 
combined with other factors in prediction models 
remains to be established by further studies.
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